Acceder

Publicaciones - Neurociencia Clínica y Experimental

Cargando...
Hernandez L, Ward LJ, Arefin S, Ebert T, Laucyte-Cibulskiene A; GOING-FWD Collaborators; Heimburger O, Barany P, Wennberg L, Stenvinkel P, Kublickiene K. Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins. Sci Rep. 2022 Mar 15;12(1):4414. doi: 10.1038/s41598-022-08387-7. PubMed PMID: 35292710; PubMed Central PMCID: PMC8924178.
AÑO: 2022; IF: 4.6
35292710
Romo-Vaquero M, Fernandez-Villalba E, Gil-Martinez AL, Cuenca-Bermejo L, Espin JC, Herrero MT, Selma MV. Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients. Food Funct. 2022 Jun 6;13(11):6306-6316. doi: 10.1039/d2fo00552b. PubMed PMID: 35611932.
AÑO: 2022; IF: 6.1
35611932
Goncalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, Martin-Balbuena S, da Silva Fernandes MJ, Scorza CA, Herrero MT. Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson's Disease. Neuroscientist. 2022 Dec;28(6):530-542. doi: 10.1177/1073858421990000. Epub 2021 Feb 15. PubMed PMID: 33583239.
AÑO: 2022; IF: 5.6
33583239
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. PubMed PMID: 34605319; PubMed Central PMCID: PMC9024029.
AÑO: 2022; IF: 5.8
34605319
de Araujo FM, Cuenca-Bermejo L, Fernandez-Villalba E, Costa SL, Silva VDA, Herrero MT. Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy. Cell Mol Neurobiol. 2022 Jul;42(5):1283-1300. doi: 10.1007/s10571-020-01027-6. Epub 2021 Jan 2. PubMed PMID: 33387119.
AÑO: 2022; IF: 4.0
33387119
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

Neurociencia Clínica y Experimental